SCHEMBL2903707

SCHEMBL2903707

Cc1sc2nc(Cl)cc(NCc3ccccn3)c2c1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.44
MAPT P10636 7/20 0.44
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
HTT P42858 1/20 0.43
ATM Q13315 1/20 0.43
NPC1 O15118 2/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KCNH2 Q12809 2/20 0.41
JAK2 O60674 1/20 0.41
IGF1R P08069 1/20 0.41
PIM1 P11309 1/20 0.41
SRC P12931 1/20 0.41
CSNK2A2 P19784 1/20 0.41
KCNA5 P22460 1/20 0.41
JAK1 P23458 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2897879 0.83 KDM4E (0.42) KDM4EMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL2897019 0.78 TNF (0.59) KDM4EMAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL3382594 0.77 KCNH2 (0.49) KDM4EMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL3385287 0.77 PRKCI (0.51) KDM4EMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL3384562 0.76 TNF (0.61) MAPTALDH1A1SMN1; SMN2HTTPOLB
SCHEMBL2905390 0.75 ALDH1A1 (0.53) KDM4EALDH1A1SMN1; SMN2HTTATM
SCHEMBL2368922 0.74 KCNH2 (0.48) SMN1; SMN2HTTATMKCNH2JAK2
SCHEMBL2368976 0.73 KCNH2 (0.48) SMN1; SMN2HTTATMKCNH2JAK2
SCHEMBL2368953 0.73 KCNH2 (0.48) SMN1; SMN2HTTATMKCNH2JAK2
SCHEMBL2368892 0.72 KCNH2 (0.48) SMN1; SMN2HTTATMKCNH2JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193215-B2 Thieno[2 3-b]pyridines as potassium channel inhibitors XENTION LIMITED (GB) 2012-06-05 US disclosed
EP-1879899-B1 THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-08-04 EP disclosed
US-20100041695-A1 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors XENTION LIMITED (GB) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041695-A1 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors SCN8A, SCN1B, SCN2B KDM4E 2290/4885MAPT 4755/4885ALDH1A1 3155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.